Case report: dynamics of acquired fluoroquinolone resistance under standardized short-course treatment of multidrug-resistant tuberculosis

Jean Claude Semuto Ngabonziza; Armand Van Deun; Patrick Migambi; Niyigena Esdras Belamo; Dusabe Théogène; Yves Mucyo Habimana; Bertin Ushizimpumu; Wim Mulders; Tom Decroo; Dissou Affolabi; Philip Supply; Bouke C de Jong; Leen Rigouts

doi:10.4269/ajtmh.20-0201

Case report: dynamics of acquired fluoroquinolone resistance under standardized short-course treatment of multidrug-resistant tuberculosis

Jean Claude Semuto Ngabonziza, Armand Van Deun, Patrick Migambi, Niyigena Esdras Belamo, Dusabe Théogène, Yves Mucyo Habimana, Bertin Ushizimpumu, Wim Mulders, Tom Decroo, Dissou Affolabi, Philip Supply, Bouke C de Jong, Leen Rigouts

Research output: Contribution to journal › A1: Web of Science-article › peer-review

30 Downloads (Pure)

Abstract

We report a case of acquired fluoroquinolone (FQ) resistance under short-course multidrug-resistant tuberculosis (MDR-TB) treatment. The patient was managed at Kabutare hospital, one of the two specialized MDR-TB clinics in Rwanda. A low dose of moxifloxacin was used in the first three critical months. Acquired resistance was identified at the ninth month of treatment, 3 months after stopping kanamycin in a strain initially susceptible only to FQs, kanamycin, and clofazimine. Fluoroquinolone resistance was detected in the same month by deep sequencing as routinely used second-line line probe assay and phenotypic drug susceptibility testing. High-dose FQ, preferably gatifloxacin, should be used to maximize effectiveness.

Original language	English
Journal	American Journal of Tropical Medicine and Hygiene
Volume	103
Issue number	4
Pages (from-to)	1443-1446
Number of pages	4
ISSN	0002-9637
DOIs	https://doi.org/10.4269/ajtmh.20-0201
Publication status	Published - 2020

Access to Document

10.4269/ajtmh.20-0201Licence: CC BY

2020ajtm1443Final published version, 63.9 KBLicence: CC BY

Cite this

Semuto Ngabonziza, J. C., Van Deun, A., Migambi, P., Belamo, N. E., Théogène, D., Habimana, Y. M., Ushizimpumu, B., Mulders, W., Decroo, T., Affolabi, D., Supply, P., de Jong, B. C., & Rigouts, L. (2020). Case report: dynamics of acquired fluoroquinolone resistance under standardized short-course treatment of multidrug-resistant tuberculosis. American Journal of Tropical Medicine and Hygiene, 103(4), 1443-1446. https://doi.org/10.4269/ajtmh.20-0201

@article{72c8e1cfd692467db8a370d96dfa1f02,

title = "Case report: dynamics of acquired fluoroquinolone resistance under standardized short-course treatment of multidrug-resistant tuberculosis",

abstract = "We report a case of acquired fluoroquinolone (FQ) resistance under short-course multidrug-resistant tuberculosis (MDR-TB) treatment. The patient was managed at Kabutare hospital, one of the two specialized MDR-TB clinics in Rwanda. A low dose of moxifloxacin was used in the first three critical months. Acquired resistance was identified at the ninth month of treatment, 3 months after stopping kanamycin in a strain initially susceptible only to FQs, kanamycin, and clofazimine. Fluoroquinolone resistance was detected in the same month by deep sequencing as routinely used second-line line probe assay and phenotypic drug susceptibility testing. High-dose FQ, preferably gatifloxacin, should be used to maximize effectiveness.",

author = "{Semuto Ngabonziza}, {Jean Claude} and {Van Deun}, Armand and Patrick Migambi and Belamo, {Niyigena Esdras} and Dusabe Th{\'e}og{\`e}ne and Habimana, {Yves Mucyo} and Bertin Ushizimpumu and Wim Mulders and Tom Decroo and Dissou Affolabi and Philip Supply and {de Jong}, {Bouke C} and Leen Rigouts",

note = "BOAC; FTX; (CC BY 4.0)",

year = "2020",

doi = "10.4269/ajtmh.20-0201",

language = "English",

volume = "103",

pages = "1443--1446",

journal = "American Journal of Tropical Medicine and Hygiene",

issn = "0002-9637",

publisher = "American Society for Tropical Medicine & Hygiene",

number = "4",

}

Semuto Ngabonziza, JC, Van Deun, A, Migambi, P, Belamo, NE, Théogène, D, Habimana, YM, Ushizimpumu, B, Mulders, W , Decroo, T, Affolabi, D, Supply, P, de Jong, BC & Rigouts, L 2020, 'Case report: dynamics of acquired fluoroquinolone resistance under standardized short-course treatment of multidrug-resistant tuberculosis', American Journal of Tropical Medicine and Hygiene, vol. 103, no. 4, pp. 1443-1446. https://doi.org/10.4269/ajtmh.20-0201

Case report: dynamics of acquired fluoroquinolone resistance under standardized short-course treatment of multidrug-resistant tuberculosis. / Semuto Ngabonziza, Jean Claude; Van Deun, Armand; Migambi, Patrick et al.
In: American Journal of Tropical Medicine and Hygiene, Vol. 103, No. 4, 2020, p. 1443-1446.

Research output: Contribution to journal › A1: Web of Science-article › peer-review

TY - JOUR

T1 - Case report: dynamics of acquired fluoroquinolone resistance under standardized short-course treatment of multidrug-resistant tuberculosis

AU - Semuto Ngabonziza, Jean Claude

AU - Van Deun, Armand

AU - Migambi, Patrick

AU - Belamo, Niyigena Esdras

AU - Théogène, Dusabe

AU - Habimana, Yves Mucyo

AU - Ushizimpumu, Bertin

AU - Mulders, Wim

AU - Decroo, Tom

AU - Affolabi, Dissou

AU - Supply, Philip

AU - de Jong, Bouke C

AU - Rigouts, Leen

N1 - BOAC; FTX; (CC BY 4.0)

PY - 2020

Y1 - 2020

N2 - We report a case of acquired fluoroquinolone (FQ) resistance under short-course multidrug-resistant tuberculosis (MDR-TB) treatment. The patient was managed at Kabutare hospital, one of the two specialized MDR-TB clinics in Rwanda. A low dose of moxifloxacin was used in the first three critical months. Acquired resistance was identified at the ninth month of treatment, 3 months after stopping kanamycin in a strain initially susceptible only to FQs, kanamycin, and clofazimine. Fluoroquinolone resistance was detected in the same month by deep sequencing as routinely used second-line line probe assay and phenotypic drug susceptibility testing. High-dose FQ, preferably gatifloxacin, should be used to maximize effectiveness.

AB - We report a case of acquired fluoroquinolone (FQ) resistance under short-course multidrug-resistant tuberculosis (MDR-TB) treatment. The patient was managed at Kabutare hospital, one of the two specialized MDR-TB clinics in Rwanda. A low dose of moxifloxacin was used in the first three critical months. Acquired resistance was identified at the ninth month of treatment, 3 months after stopping kanamycin in a strain initially susceptible only to FQs, kanamycin, and clofazimine. Fluoroquinolone resistance was detected in the same month by deep sequencing as routinely used second-line line probe assay and phenotypic drug susceptibility testing. High-dose FQ, preferably gatifloxacin, should be used to maximize effectiveness.

U2 - 10.4269/ajtmh.20-0201

DO - 10.4269/ajtmh.20-0201

M3 - A1: Web of Science-article

C2 - 32618257

SN - 0002-9637

VL - 103

SP - 1443

EP - 1446

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

IS - 4

ER -

Case report: dynamics of acquired fluoroquinolone resistance under standardized short-course treatment of multidrug-resistant tuberculosis

Abstract

Access to Document

Fingerprint

Cite this